Medimix reached out to Prof Eric Van Cutsem, UZ Gasthuisberg, and Prof Deborah Schrag from the Memorial Sloan Kettering Cancer Center to discuss the PROSPECT study.
This study is a randomized phase III trial that aims to compare neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision. The study is aimed at treating locally advanced rectal cancer.
With the educational support of:
